Evidence map›Paper›PMID 31165425›Full record

ArticleCEN case reports2019

Hemophagocytic syndrome with acute kidney injury accompanied by erythrophagocytic macrophages in the tubular lumen.

Hiroyuki Hashimoto, Takeshi Sugiura, Hideki Matsushima

Abstract readCase Reports
In one paragraph

Article in CEN case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hiroyuki HashimotoDepartment of Nephrology, Seirei Mikatahara General Hospital, 3454, Mikatahara, Kita-ku, Hamamatsu, Shizuoka, 433-8558, Japan. naruhodo.hasshi777@gmail.com.
Takeshi SugiuraDepartment of Nephrology, Seirei Mikatahara General Hospital, 3454, Mikatahara, Kita-ku, Hamamatsu, Shizuoka, 433-8558, Japan.
Hideki MatsushimaDepartment of Nephrology, Seirei Mikatahara General Hospital, 3454, Mikatahara, Kita-ku, Hamamatsu, Shizuoka, 433-8558, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophagocytic syndrome (HPS) is a life-threatening syndrome involving excessive immune activation. It is often accompanied by renal involvement known as acute kidney injury (AKI), which is a poor prognostic factor of HPS. Thus, early diagnosis and treatment are very important. However, it is rarely identified in renal biopsy specimens, and its major manifestation is acute tubular necrosis. We report a rare case of erythrophagocytic macrophage presence in the tubular lumen of a patient with HPS-associated AKI. A kidney biopsy showed acute tubular necrosis, interstitial massive macrophage infiltration, and phagocytic macrophage casts without glomerular change. Some arteriolar vascular smooth muscle cells showed vacuolization because they were positive for α-smooth muscle actin. The patient's renal function improved after methylprednisolone pulse therapy followed by oral prednisolone after a month. Our case presents a new pathologic pattern of HPS. Careful urinalysis could suggest renal involvement with HPS. Having knowledge of this pathologic pattern of HPS is important to recognize the disease and to treat it appropriately.

Indexed as

ActinsAcute Kidney InjuryAdultEarly DiagnosisFemaleGlucocorticoidsHumansKidneyKidney GlomerulusKidney Tubular Necrosis, AcuteLymphohistiocytosis, HemophagocyticMacrophagesMethylprednisoloneTreatment OutcomeACTA2 protein, humanActinsGlucocorticoidsMethylprednisoloneAcute kidney injuryAcute tubular injuryAcute tubular necrosisHemophagocytic syndromeHemophagocytosisHistiocytic glomerulopathyKidney biopsyMacrophage activation syndrome

Identifiers

PMID31165425
PMCPMC6820652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.